Charles River Laboratories International
The 10-second takeaway
For the quarter ended Dec. 29 (Q4), Charles River Laboratories International met expectations on revenues and beat expectations on earnings per share.
Compared to the prior-year quarter, revenue shrank and GAAP earnings per share dropped significantly.
Margins shrank across the board.
Charles River Laboratories International chalked up revenue of $280.1 million. The 11 analysts polled by S&P Capital IQ expected revenue of $281.1 million on the same basis. GAAP reported sales were the same as the prior-year quarter's.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.64. The 15 earnings estimates compiled by S&P Capital IQ predicted $0.60 per share. GAAP EPS of $0.38 for Q4 were 31% lower than the prior-year quarter's $0.55 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 32.5%, 230 basis points worse than the prior-year quarter. Operating margin was 12.5%, 810 basis points worse than the prior-year quarter. Net margin was 6.6%, 270 basis points worse than the prior-year quarter.
Next quarter's average estimate for revenue is $292.4 million. On the bottom line, the average EPS estimate is $0.71.
Next year's average estimate for revenue is $1.18 billion. The average EPS estimate is $2.90.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Charles River Laboratories International is outperform, with an average price target of $42.04.
Looking for alternatives to Charles River Laboratories International? It takes more than great companies to build a fortune for the future. Learn the basic financial habits of millionaires next door and get focused stock ideas in our free report, "3 Stocks That Will Help You Retire Rich." Click here for instant access to this free report.
- Add Charles River Laboratories International to My Watchlist.